



Fermiscan Holdings Limited  
ABN 51 000 689 725

Level 7  
48 Hunter Street  
Sydney NSW 2000

t. +61 2 9245 4460  
f. +61 2 9209 4353

[www.fermiscan.com.au](http://www.fermiscan.com.au)

## **ASX ANNOUNCEMENT**

**22 September 2009**

### **Director resignation**

Mr Gary Garton has resigned from the Fermiscan Holdings Limited board.

Mr Garton has been the Chairman of Fermiscan Holdings Limited since October 2006.

The board wishes to express its appreciation to Mr Garton for the contribution he has made in the formative years of Fermiscan.

As noted in a previous announcement on 17 September 2009, the Fermiscan board has appointed Mr Ian Chalmers and Mr Mark Fordree to the board.

Under the new board the company has focused on reducing overheads and has streamlined its operations to be fully focused on the commercialisation of the Fermiscan Test. The new board appointments reflect the board's policy on renewal to ensure the board remains open to new ideas and independent thinking and to make sure the skills sets and experience are consistent with the commercial and other circumstances of Fermiscan.

Leon Carr  
Executive Director  
Visit Fermiscan's website at [www.fermiscan.com.au](http://www.fermiscan.com.au)

## **About Fermiscan**

Fermiscan's principal interest is the commercialisation of an innovative non-invasive diagnostic test for the detection of breast cancer.

The Fermiscan Breast Cancer Test is based on the discovery by an Australian scientist that a change can be detected in the molecular structure of hair from women with breast cancer and this change can be identified by using diffraction of X-rays generated in a synchrotron.

Fermiscan completed a major clinical trial of the Fermiscan Test in May 2008, with sensitivity (ability to accurately detect cancer) of 74% in women under 70, and with a higher sensitivity for younger women; and specificity (ability to accurately detect the absence of cancer - negative predictive value) of 99.5%.

Fermiscan is developing opportunities to licence and sell the Fermiscan Test internationally, particularly in Australia, Europe, Japan, South East Asia, and the United States.

Fermiscan owns and operates the Sydney Breast Clinic, one of the largest diagnostic breast clinics in Australia that for more than 30 years has been caring for over 10,000 women annually.

## **Recent announcements**

- Mr Ian Chalmers and Mr Mark Fordree appointed to the board
- Fermiscan announced in July 2009 the commencement of a pre-commercialisation pilot for the Fermiscan Breast Cancer Test in Australia, aimed at gathering information on the use of the test in the clinical setting of General Practice
- Patents granted in Japan and European Community countries
- Exclusive option agreement to licence the Fermiscan Test to Hitachi Chemical in Japan and Korea granted in March 2009
- Italian independent study with sensitivity (ability to accurately detect cancer) of 83% and specificity (ability to accurately detect the absence of cancer) of 76%
- Independent European multi-centre trial of the Fermiscan Test is underway and these should support commercialisation in Italy and Europe
- European CE Mark registration of the Fermiscan Test completed in July 2009
- Australian Synchrotron agreement signed in February 2009 securing beamline access for two years
- Named 2008 'Australian Innovator of the year' at the Austrade sponsored annual 'Innovation Day Shoot Out' competition in New York

Fermiscan is a member of the Australian Technology Showcase, a national program aimed at promoting and developing export markets for innovative technology based products. Fermiscan has received support from the NSW Department of State and Regional Development through its various programs such as BioBusiness and BioFirst

Visit Fermiscan's website at [www.fermiscan.com.au](http://www.fermiscan.com.au)

Visit Sydney Breast Clinic's website at [www.sydneybreastclinic.com.au](http://www.sydneybreastclinic.com.au)